Mevrometostat trial for hormone-resistant prostate cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with castration-resistant prostate cancer (confirmed by biopsy or other cell test).
- You’re well enough to do most activities (ECOG 0 to 2) and your doctor expects you can live at least 6 months.
- Your blood counts and kidney and liver tests must be adequate.
- You have not had radiation that covered more than 25% of your bone marrow.
- Your heart rhythm test (QTcF) must not be higher than 480 milliseconds, and blood pressure must be controllable.
- You cannot have certain stomach or gut conditions (like active inflammatory bowel disease or certain stomach surgeries) or specific medication interactions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This study tests a new drug called mevrometostat combined with enzalutamide in men whose prostate cancer has spread and is no longer responding to previous hormone-blocking treatments. The goal is to see if adding mevrometostat helps slow cancer growth when enzalutamide alone is no longer working.
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Hear when a new Metastatic Castration Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.